title: Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA.
abstract: An alemtuzumab-based experimental immunosuppressive treatment (IST) regimen was investigated in 35 patients with severe aplastic anaemia (SAA), pure red cell (PRCA) or pure white cell aplasia (PWCA). Alemtuzumab total dose was 73-103 mg s.c., followed by cyclosporine. No serious toxicity due to the regimen was observed. Adverse events were clinically irrelevant; infectious events were rare. The total response rate was 58%, 84% and 100% in SAA, PRCA and PWCA, respectively, with corresponding 6 months cumulative response probabilities of 84%, 84% and 100%. Subcutaneous alemtuzumab is a feasible and sufficiently safe IST regimen for patients suffering from immune-mediated marrow failures.
authors.affiliation: Department of Biochemistry and Medical Biotechnologies, Federico II University of Naples, Italy. amrisita@unina.it <amrisita@unina.it>
authors.forename: Antonio Maria
authors.initials: AM
authors.lastname: Risitano
authors.forename: Carmine
authors.initials: C
authors.lastname: Selleri
authors.forename: Bianca
authors.initials: B
authors.lastname: Serio
authors.forename: Giovanni Fernando
authors.initials: GF
authors.lastname: Torelli
authors.forename: Alexander
authors.initials: A
authors.lastname: Kulagin
authors.forename: Sébastien
authors.initials: S
authors.lastname: Maury
authors.forename: Jörg
authors.initials: J
authors.lastname: Halter
authors.forename: Vikas
authors.initials: V
authors.lastname: Gupta
authors.forename: Andrea
authors.initials: A
authors.lastname: Bacigalupo
authors.forename: Gerard
authors.initials: G
authors.lastname: Sociè
authors.forename: André
authors.initials: A
authors.lastname: Tichelli
authors.forename: Hubert
authors.initials: H
authors.lastname: Schrezenmeier
authors.forename: Judith
authors.initials: J
authors.lastname: Marsh
authors.forename: Jakob
authors.initials: J
authors.lastname: Passweg
authors.forename: Bruno
authors.initials: B
authors.lastname: Rotoli
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000074323:Alemtuzumab; D000741:Anemia, Aplastic / Q000188:drug therapy*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects / Q000627:therapeutic use*; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011446:Prospective Studies
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D007166:Immunosuppressive Agents; D000074323:Alemtuzumab; D016572:Cyclosporine